Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2019-12-27

FDA Approved: LYNPARZA — Supplemental Application (AstraZeneca Pharmaceuticals LP)

View source ↗

Summary

FDA approved a supplemental application for LYNPARZA (olaparib) from AstraZeneca Pharmaceuticals LP. The approval updates the product labeling as described in t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lynparza (olaparib)

Snippet

SUPPL AP for LYNPARZA (OLAPARIB)